MedPath

Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors

Phase 4
Conditions
Ssri
Neuronal Plasticity
Interventions
Drug: Placebo
Drug: Escitalopram
Other: 3xMR scan (fMRI, DTI, strucutral MRI)
Behavioral: Association learning paradigm
Behavioral: Association re-learning paradigm
First Posted Date
2016-04-28
Last Posted Date
2016-04-28
Lead Sponsor
Medical University of Vienna
Target Recruit Count
80
Registration Number
NCT02753738
Locations
🇦🇹

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

Study of Neural Responses Induced by Antidepressant Effects

Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: Escitalopram
Behavioral: Real-time Neurofeedback fMRI task pre- and post-RCT
First Posted Date
2016-02-04
Last Posted Date
2022-11-03
Lead Sponsor
Marta Peciña, MD PhD
Target Recruit Count
60
Registration Number
NCT02674529
Locations
🇺🇸

WPIC, Pittsburgh, Pennsylvania, United States

The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients

Phase 2
Conditions
GBM
Depression
Interventions
Drug: Escitalopram
Drug: placebo
First Posted Date
2015-12-07
Last Posted Date
2015-12-07
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
100
Registration Number
NCT02623231
Locations
🇮🇱

The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Advancing Personalized Antidepressant Treatment Using PET/MRI

Phase 4
Completed
Conditions
Depression
Interventions
Drug: Placebo
Drug: Escitalopram
First Posted Date
2015-12-07
Last Posted Date
2022-12-15
Lead Sponsor
Stony Brook University
Target Recruit Count
85
Registration Number
NCT02623205
Locations
🇺🇸

Stony Brook University Hospital, Stony Brook, New York, United States

SSRI Effects on Depression and Immunity in HIV/AIDS

Phase 4
Completed
Conditions
Depression
AIDS
HIV
Interventions
Drug: Escitalopram
Other: Placebo
First Posted Date
2015-12-02
Last Posted Date
2024-05-07
Lead Sponsor
University of Pennsylvania
Target Recruit Count
108
Registration Number
NCT02620150
Locations
🇺🇸

University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

Not Applicable
Completed
Conditions
Depression
Anxiety
Bipolar Disorder
Interventions
Behavioral: Cognitive behavioral Psychotherapy
Drug: Escitalopram
First Posted Date
2015-09-17
Last Posted Date
2024-02-26
Lead Sponsor
University of Cincinnati
Target Recruit Count
214
Registration Number
NCT02553161
Locations
🇺🇸

Stanford University, Stanford, California, United States

🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

Not Applicable
Completed
Conditions
Anxiety
Cardiovascular Disease
Interventions
Behavioral: Supervised Aerobic Exercise
Drug: Placebo
Drug: Lexapro
First Posted Date
2015-08-05
Last Posted Date
2021-06-11
Lead Sponsor
Duke University
Target Recruit Count
128
Registration Number
NCT02516332
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression

Not Applicable
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2015-06-24
Last Posted Date
2015-06-24
Lead Sponsor
Abarbanel Mental Health Center
Target Recruit Count
52
Registration Number
NCT02480400
Locations
🇮🇱

Abarbanel MHC, Bat-Yam, Israel

Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment

First Posted Date
2015-06-11
Last Posted Date
2018-09-07
Lead Sponsor
Medical University of Bialystok
Target Recruit Count
60
Registration Number
NCT02469545
Locations
🇵🇱

Department of Psychiatry, Medical University of Bialystok, Bialystok, Poland

The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)

Phase 2
Terminated
Conditions
End Stage Renal Disease
Interventions
Drug: Escitalopram
Drug: Placebo
First Posted Date
2015-04-03
Last Posted Date
2018-10-11
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
25
Registration Number
NCT02407821
Locations
🇨🇦

St. Michael's Hospital, Toronto, Ontario, Canada

🇨🇦

University Health Network, Toronto, Ontario, Canada

🇨🇦

St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath